Xoma Corp Receives a Hold from Cowen & Co.


In a report released today, Phil Nadeau from Cowen & Co. maintained a Hold rating on Xoma Corp (NASDAQ: XOMA). The company’s shares opened today at $22.64.

According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 12.4% and a 51.6% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Voyager Therapeutics Inc, and Adverum Biotechnologies.

Xoma Corp has an analyst consensus of Moderate Buy, with a price target consensus of $49.

See today’s analyst top recommended stocks >>

Based on Xoma Corp’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $1.32 million. In comparison, last year the company had a GAAP net loss of $10.72 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

XOMA Corp. engages in the discovery and development of innovative therapeutics derived from unique platform of antibody technologies. Its products includes X358, X213, X129, and gevokizumab. The company was founded by Patrick J. Scannon in 1981 and is headquartered in Berkeley, CA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts